Background diabetic retinopathy
diseaseOn this page
Also known as non-proliferative diabetic retinopathy
Summary
Background diabetic retinopathy (MONDO:0001661) is a disease and 38 clinical trials. Top therapeutic interventions include bevacizumab, prednisolone acetate, and dexamethasone sodium phosphate. A subtype of diabetic retinopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 38
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | background diabetic retinopathy |
| Mondo ID | MONDO:0001661 |
| DOID | DOID:13208 |
| NCIT | C35668 |
| SNOMED CT | 390834004 |
| UMLS | C0004606 |
| MedGen | 2531 |
| Is cancer (heuristic) | no |
Also known as: non-proliferative diabetic retinopathy
Disease family
This is a subtype of diabetic retinopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal vascular disorder › diabetic retinopathy › background diabetic retinopathy
Related subtypes (2): proliferative diabetic retinopathy, diabetic macular edema
Subtypes (1): severe nonproliferative diabetic retinopathy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 38.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 12 |
| PHASE2 | 8 |
| PHASE4 | 7 |
| PHASE3 | 7 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00563043 | PHASE4 | TERMINATED | Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment |
| NCT00563628 | PHASE4 | TERMINATED | Changes in Macular Thickness After Patterns Scan Laser |
| NCT01921192 | PHASE4 | UNKNOWN | Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy |
| NCT02096874 | PHASE4 | COMPLETED | Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema |
| NCT05358080 | PHASE4 | UNKNOWN | Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy |
| NCT05386160 | PHASE4 | UNKNOWN | Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy |
| NCT07230184 | PHASE4 | COMPLETED | To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR |
| NCT06817265 | PHASE3 | RECRUITING | Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy |
| NCT06951087 | PHASE3 | ENROLLING_BY_INVITATION | Intravitreal and Intracameral DEX in NPDR |
| NCT07235085 | PHASE3 | RECRUITING | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy |
| NCT01853072 | PHASE3 | COMPLETED | Nepafenac Once Daily for Macular Edema - Study 1 |
| NCT01872611 | PHASE3 | COMPLETED | Nepafenac Once Daily for Macular Edema - Study 2 |
| NCT02388984 | PHASE3 | UNKNOWN | Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy |
| NCT04511715 | PHASE2/PHASE3 | UNKNOWN | Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy |
| NCT05066230 | PHASE3 | TERMINATED | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) |
| NCT05393284 | PHASE2 | ACTIVE_NOT_RECRUITING | Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy |
| NCT07236645 | PHASE2 | NOT_YET_RECRUITING | Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy |
| NCT07259928 | PHASE2 | RECRUITING | Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion |
| NCT07354477 | PHASE2 | RECRUITING | Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation |
| NCT01571232 | PHASE2 | COMPLETED | Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema |
| NCT02062034 | PHASE2 | COMPLETED | Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy |
| NCT02435862 | PHASE2 | COMPLETED | A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy |
| NCT05681884 | PHASE2 | COMPLETED | Safety and Efficacy of Faricimab in Patients With NPDR |
| NCT05695417 | PHASE1 | UNKNOWN | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy |
| NCT06487845 | PHASE1 | COMPLETED | A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants |
| NCT07198815 | EARLY_PHASE1 | NOT_YET_RECRUITING | A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy |
| NCT05852132 | Not specified | NOT_YET_RECRUITING | Clinical Study on Prognosis of Patients With Severe NPDR Undergoing Vitrectomy |
| NCT06713720 | Not specified | RECRUITING | Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy |
| NCT01107132 | Not specified | UNKNOWN | Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus |
| NCT01145599 | Not specified | COMPLETED | Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures |
| NCT01646047 | Not specified | COMPLETED | Diabetes Visual Function Supplement Study |
| NCT01759121 | Not specified | UNKNOWN | Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR |
| NCT01880372 | Not specified | TERMINATED | The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy |
| NCT02309502 | Not specified | WITHDRAWN | Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy |
| NCT03597815 | Not specified | UNKNOWN | Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study |
| NCT04000789 | Not specified | UNKNOWN | The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR) |
| NCT04103671 | Not specified | UNKNOWN | Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR |
| NCT05222633 | Not specified | UNKNOWN | Anti-VEGF in Real-world |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BEVACIZUMAB | 4 | 2 |
| PREDNISOLONE ACETATE | 4 | 2 |
| DEXAMETHASONE SODIUM PHOSPHATE | 4 | 1 |
| FARICIMAB | 4 | 1 |
| HYALURONATE SODIUM | 4 | 1 |
| NEPAFENAC | 4 | 1 |
| RETINOL | 4 | 1 |
| CONBERCEPT | 3 | 1 |
| LIPOIC ACID, ALPHA | 3 | 1 |
| TARCOCIMAB TEDROMER | 3 | 1 |
| UBIDECARENONE | 3 | 1 |
| CHEMBL1200637 | 0 | 1 |
| CHEMBL4743806 | 0 | 1 |
| S-ROLIPRAM | 0 | 1 |